Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Radionuclide Therapy | Research article

Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review

Authors: Zohreh Maghsoomi, Zahra Emami, Ramin Malboosbaf, Mojtaba Malek, Mohammad E. Khamseh

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

It has been shown that a subgroup of patients with differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC) would progress to advanced stages of thyroid cancer. Therefore, the present study was done to systematically review available evidence in order to investigate efficacy and safety of peptide receptor radionuclide therapy (PRRT) in the patients with advanced radioiodine refractory differentiated thyroid cancer (RR-DTC) and metastatic MTC.

Methods

For this purpose, relevant studies investigated safety and efficacy of PRRT in the patients with advanced RR-DTC and metastatic MTC were identified by searching Medline (Pubmed, Ovid, and Ebsco), Scopus, Embase, Web of Science, and Cochrane Library databases (from database inception to March 24, 2021). The review was performed according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement. Searching was done independently by two investigators. Two researchers independently extracted the data and any disagreement was adjudicated by consensus. Quality of the studies was assessed using the tool of case reports/series in systematic reviews.

Results

Among 2284 related papers, 41 papers met the inclusion criteria. A total of 157 patients with RR-DTC were treated with PPRT. Biochemical and objective responses (partial and complete) were observed in 25.3 and 10.5% of patients, respectively. Among 220 patients with metastatic MTC, biochemical and objective responses were observed in 37.2 and 10.6% of the patients, respectively.

Forty-six deaths were reported in 95 patients with advanced RR-DTC. In addition, 63 deaths were observed in 144 patients with metastatic MTC. Major side effects were reported in 124 patients treated with ⁹⁰Y -based agent. In the patients treated with 177Lu-DOTA-TATE and 111In-Octreotide, mild and transient hematologic or renal complications were reported.

Conclusion

Findings of the study revealed that in the absence of the established treatment for the patients with RR-DTC and metastatic MTC, PRRT could be effective with few adverse events.

Trial registration

PROSPERO registration number: CRD42019125245.

Available only for authorised users

Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al (eds). SEER Cancer Statistics Review, 1975-2011. Bethesda: National Cancer Institute; 2014. https://seer.cancer.gov/archive/csr/1975_2011/.

Atlanta G. Cancer facts and figures; 2015.

Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338(5):297–306. https://doi.org/10.1056/NEJM199801293380506.CrossRefPubMed

Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Curr Opin Oncol. 2008;20(1):19–24. https://doi.org/10.1097/CCO.0b013e3282f28373.CrossRefPubMed

Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer. 1998;83(12):2638–48. https://doi.org/10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1.CrossRefPubMed

Budiawan H, Salavati A, Kulkarni HR, Baum RP. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90) yttrium and (177) lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am J Nucl Med Mol Imaging. 2013;4(1):39–52.PubMedPubMedCentral

Salavati A, Puranik A, Kulkarni HR, Budiawan H, Baum RP. Peptide receptor radionuclide therapy (PRRT) of medullary and nonmedullary thyroid cancer using radiolabeled somatostatin analogues. Semin Nuclear Med. 2016;46(3):215–24. https://doi.org/10.1053/j.semnuclmed.2016.01.010.

Silberstein EB. The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome. Semin Nucl Med. 2011;41(2):113–20. https://doi.org/10.1053/j.semnuclmed.2010.10.002.CrossRefPubMed

Sherman SI. Thyroid carcinoma. Lancet. 2003;361(9356):501–11.CrossRef

10.

Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–9. https://doi.org/10.1210/jc.2005-2838.CrossRefPubMed

11.

Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F, et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab. 2002;87(9):4160–5. https://doi.org/10.1210/jc.2001-011151.CrossRefPubMed

12.

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. https://doi.org/10.1089/thy.2015.0020.CrossRefPubMedPubMedCentral

13.

Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. Oncologist. 2008;13(5):539–47. https://doi.org/10.1634/theoncologist.2007-0239.CrossRefPubMed

14.

Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008;4(1):22–32. https://doi.org/10.1038/ncpendmet0717.CrossRefPubMed

15.

Czepczynski R, Matysiak-Grzes M, Gryczynska M, Baczyk M, Wyszomirska A, Stajgis M, et al. Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity. Arch Immunol Ther Exp. 2015;63(2):147–54. https://doi.org/10.1007/s00005-014-0318-6.CrossRef

16.

Satapathy S, Mittal BR, Bhansali A. Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis. Clin Endocrinol. 2019;91(6):718–27. https://doi.org/10.1111/cen.14106.

17.

Gulenchyn K, Yao X, Asa S, Singh S, Law C. Radionuclide therapy in neuroendocrine tumours: a systematic review. Clin Oncol. 2012;24(4):294–308. https://doi.org/10.1016/j.clon.2011.12.003.CrossRef

18.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRef

19.

Julka PK, Doval DC, Gupta S, Rath GK. Response assessment in solid tumours: a comparison of WHO, SWOG and RECIST guidelines. Br J Radiol. 2008;81(966):444–9. https://doi.org/10.1259/bjr/32785946.CrossRefPubMed

20.

Pinker K, Riedl C, Weber WA. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):55–66. https://doi.org/10.1007/s00259-017-3687-3.CrossRefPubMedPubMedCentral

21.

Institute NC. Common terminology criteria for adverse events (CTCAE) version 4.0. National Cancer Institute Enterprise Vocabulary Services website. 2010.

22.

Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60–3. https://doi.org/10.1136/bmjebm-2017-110853.CrossRefPubMedPubMedCentral

23.

Versari A, Sollini M, Frasoldati A, Fraternali A, Filice A, Froio A, et al. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Thyroid. 2014;24(4):715–26. https://doi.org/10.1089/thy.2013.0225.CrossRefPubMed

24.

Iten F, Muller B, Schindler C, Rasch H, Rochlitz C, Oertli D, et al. (90) yttrium-DOTA -TOC response is associated with survival benefit in iodine-refractory thyroid Cancer long-term results of a phase 2 clinical trial. Cancer. 2009;115(10):2052–62. https://doi.org/10.1002/cncr.24272.CrossRefPubMed

25.

Gabriel M, Froehlich F, Decristoforo C, Ensinger C, Donnemiller E, von Guggenberg E, et al. 99mTc-EDDA/HYNIC-TOC and (18) F-FDG in thyroid cancer patients with negative (131) I whole-body scans. Eur J Nucl Med Mol Imaging. 2004;31(3):330–41. https://doi.org/10.1007/s00259-003-1376-x.CrossRefPubMed

26.

Gorges R, Kahaly G, Muller-Brand J, Macke H, Roser HW, Bockisch A. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid. 2001;11(7):647–59. https://doi.org/10.1089/105072501750362718.CrossRefPubMed

27.

Waldherr C, Schumacher T, Pless M, Crazzolara A, Maecke HR, Nitzsche EU, et al. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using. Nucl Med Commun. 2001;22(6):673–8. https://doi.org/10.1097/00006231-200106000-00011.CrossRefPubMed

28.

Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002;32(2):148–55. https://doi.org/10.1053/snuc.2002.31565.CrossRefPubMed

29.

Traub-Weidinger T, Raderer M, Uffmann M, Angelberger P, Kurtaran A, Leimer M, et al. Improved quality of life in patients treated with peptide radionuclides. World J Nucl Med. 2011;10(2):115–21. https://doi.org/10.4103/1450-1147.89779.CrossRefPubMedPubMedCentral

30.

Basu S, Parghane RV, Naik C. Clinical efficacy of (177) Lu-DOTATATE peptide receptor radionuclide therapy in thyroglobulin-elevated negative iodine scintigraphy: a "not-so-promising" result compared to GEP-NETs. World J Nucl Med. 2020;19(3):205–10. https://doi.org/10.4103/wjnm.WJNM_21_19.CrossRefPubMedPubMedCentral

31.

Cinkir HY, Elboga U. An alternative therapy option in metastatic thyroid Cancer: peptide receptor radionuclide therapy. J Istanb Fac Med. 2020;83(4):339–44.

32.

Roll W, Riemann B, Schäfers M, Stegger L, Vrachimis A. 177Lu-DOTATATE therapy in radioiodine-refractory differentiated thyroid Cancer: a single center experience. Clin Nucl Med. 2018;43(10):e346–e51. https://doi.org/10.1097/RLU.0000000000002219.CrossRefPubMed

33.

Olivan-Sasot P, Falgas-Lacueva M, Garcia-Sanchez J, Vera-Pinto V, Olivas-Arroyo C, Bello-Arques P. Use of (177) Lu-dotatate in the treatment of iodine refractory thyroid carcinomas. Rev Esp Med Nucl Imagen Mol. 2017;36(2):116–9. https://doi.org/10.1016/j.remn.2016.08.001.CrossRefPubMed

34.

Elboğa U, Özkaya M, Sayiner ZA, Çelen YZ. Lu-177 labelled peptide treatment for radioiodine refractory differentiated thyroid carcinoma. BMJ Case Rep. 2016;8;2016:bcr2015213627. https://doi.org/10.1136/bcr-2015-213627.

35.

Jois B, Asopa R, Basu S. Somatostatin receptor imaging in non–131I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with 177Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of Chromogranin a level–positive neuroendocrine differentiation. Clin Nucl Med. 2014;39(6):505–10. https://doi.org/10.1097/RLU.0000000000000429.CrossRefPubMed

36.

Teunissen JJ, Kwekkeboom DJ, Kooij PP, Bakker WH, Krenning EP. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. J Nucl Med. 2005;46(Suppl 1):107s–14s.PubMed

37.

Parihar AS, Sood A, Kumar R, Bhusari P, Shukla J, Mittal BR. Novel use of (177) Lu-DOTA-RGD2 in treatment of (68) Ga-DOTA-RGD2-avid lesions in papillary thyroid cancer with TENIS. Eur J Nucl Med Mol Imaging. 2018;45(10):1836–7. https://doi.org/10.1007/s00259-018-4036-x.CrossRefPubMed

38.

Campennì A, Pignata SA, Baldari S. Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer? Endocrine. 2015;50(2):516–8. https://doi.org/10.1007/s12020-014-0491-8.CrossRefPubMed

39.

Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [in-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32(2):110–22. https://doi.org/10.1053/snuc/2002.31025.CrossRefPubMed

40.

Krenning E, De Jong M, Kooij P, Breeman W, Bakker W, De Herder W, et al. Radiolabelled somatostatin analogue (s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10(suppl_2):S23–S9.CrossRef

41.

Stokkel MP, Verkooijen RB, Bouwsma H, Smit JW. Six month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer: a pilot study. Nucl Med Commun. 2004;25(7):683–90. https://doi.org/10.1097/01.mnm.0000130244.14444.5e.CrossRefPubMed

42.

Scalorbi F, Filice F, Sollini M, Menga M. Peptide receptor radionuclide therapy (PRRT) in metastatic thyroid tumors: an opportunity after traditional treatment failure. Clin Transl Imaging. 2017;5(Suppl 1):S100.

43.

Öksüz M, Winter L, Pfannenberg C, Reischl G, Müssig K, Bares R, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC? 2014;95(3):289–300.

44.

Bertagna F, Giubbini R, Savelli G, Pizzocaro C, Rodella C, Biasiotto G, et al. A patient with medullary thyroid carcinoma and right ventricular cardiac metastasis treated by (90) Y-Dotatoc. Hell J Nucl Med. 2009;12(2):161–4.PubMed

45.

Iten F, Muller B, Schindler C, Rochlitz C, Oertli D, Macke HR, et al. Response to (90) yttrium-DOTA -TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007;13(22):6696–702. https://doi.org/10.1158/1078-0432.CCR-07-0935.CrossRefPubMed

46.

Bodei L, Handkiewicz-Junak D, Grana C, Mazzetta C, Rocca P, Bartolomei M, et al. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm. 2004;19(1):65–71. https://doi.org/10.1089/108497804773391694.CrossRefPubMed

47.

Gao ZR, Biersack HJ, Ezziddin S, Logvinski T, An R. The role of combined imaging in metastatic medullary thyroid carcinoma: In-111-DTPA-octreotide and I-131/I-123-MIBG as predictors for radionuclide therapy. J Cancer Res Clin Oncol. 2004;130(11):649–56. https://doi.org/10.1007/s00432-004-0588-1.CrossRefPubMed

48.

Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26(11):1439–47. https://doi.org/10.1007/s002590050476.CrossRefPubMed

49.

Bilgic S, Saǧer MS, Beytur MF, Nazari A, Uslu Beşli RL, Asa S, et al. The effectiveness of 177Lu-DOTATATE in patients with metastatic medullary thyroid cancer. Eur J Nucl Med Mol Imaging. 2020;47(SUPPL 1):S27–S8.

50.

Parghane RV, Naik C, Talole S, Desmukh A, Chaukar D, Banerjee S, et al. Clinical utility of Lu-177-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity. Head Neck-J Sci Spec Head Neck. 2020;42(3):401–16. https://doi.org/10.1002/hed.26024.CrossRef

51.

Makis W, McCann K, McEwan AJ. Medullary thyroid carcinoma (MTC) treated with 177Lu-DOTATATE PRRT: a report of two cases. Clin Nucl Med. 2015;40(5):408–12. https://doi.org/10.1097/RLU.0000000000000706.CrossRefPubMed

52.

Vaisman F, Rosado de Castro PH, Lopes FP, Kendler DB, Pessoa CH, Bulzico DA, et al. Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer? Clin Nucl Med. 2015;40(2):123–7. https://doi.org/10.1097/RLU.0000000000000628.CrossRefPubMed

53.

Soydal Ç, Peker A, Özkan E, Küçük ÖN, Kir MK. The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with lu-177 DOTATATE. Turkish J Med Sci. 2016;46(2):409–13. https://doi.org/10.3906/sag-1412-11.CrossRef

54.

Beukhof CM, Brabander T, van Nederveen FH, van Velthuysen MF, de Rijke YB, Hofland LJ, et al. Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls. BMC Cancer. 2019;19(1):325. https://doi.org/10.1186/s12885-019-5540-5.CrossRefPubMedPubMedCentral

55.

Mathew D, Hephzibah J, Shanthly N, Oommen R. Overview of peptide receptor radionuclide therapy with 177Lutetium-DOTATATE in our institution: 4 years' experience. Indian J Nucl Med. 2018;33(5):S65.

56.

Pasieka JL, McEwan AJB, Rorstad O. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery. 2004;136(6):1218–26. https://doi.org/10.1016/j.surg.2004.06.050.CrossRefPubMed

57.

Caplin M, Mielcarek W, Buscombe J, Jones A, Croasdale P, Cooper M, et al. Toxicity of high-activity 111In-Octreotide therapy in patients with disseminated neuroendocrine tumours. Nucl Med Commun. 2000;21(1):97–102. https://doi.org/10.1097/00006231-200001000-00016.CrossRefPubMed

58.

Buscombe JR, Caplin ME, Hilson AJW. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med. 2003;44(1):1–6.PubMed

59.

Hayes AR, Crawford A, Al Riyami K, Tang C, Wild D, Khoo B, et al. Metastatic medullary thyroid cancer (MTC): is there a role for peptide receptor radionuclide therapy (PRRT)? Neuroendocrinology. 2019;108:273.

60.

Puranik A, Baum RP, Kulkarni H, Singh A, Rangarajan V, Agrawal A, et al. Peptide receptor radionuclide therapy using 177Lu and 90Y-DOTATATE in metastatic treatment-refractory medullary thyroid cancer. Neuroendocrinology. 2019;108:228.

61.

Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90 Y-DOTATOC and 177 Lu-DOTATATE: the role of associated risk factors. 2008;35(10):1847–56.

62.

Weitzman SP, Sherman SI. Novel drug treatments of progressive radioiodine-refractory differentiated thyroid Cancer. Endocrinol Metab Clin N Am. 2019;48(1):253–68. https://doi.org/10.1016/j.ecl.2018.10.009.CrossRef

63.

Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol. 2010;22(6):464–8. https://doi.org/10.1016/j.clon.2010.03.014.CrossRef

64.

de Vries LH, Lodewijk L, Willems SM, Dreijerink KMA, de Keizer B, van Diest PJ, et al. SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival. Endocrine. 2018;62(3):639–47. https://doi.org/10.1007/s12020-018-1706-1.CrossRefPubMedPubMedCentral

65.

Forssell-Aronsson EB, Nilsson O, Bejegard SA, Kolby L, Bernhardt P, Molne J, et al. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med. 2000;41(4):636–42.PubMed

66.

Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90) Y-DOTA (0),Tyr (3)-octreotide and (177) Lu-DOTA (0), Tyr (3)-octreotate. J Nucl Med. 2005;46(Suppl 1):83s–91s.PubMed

Title: Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
Authors: Zohreh Maghsoomi
Zahra Emami
Ramin Malboosbaf
Mojtaba Malek
Mohammad E. Khamseh
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Radionuclide Therapy
Thyroid Cancer
Thyroid Cancer
Thyroid Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08257-x

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2021

Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review

Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1

The opposing action of stromal cell proenkephalin and stem cell transcription factors in prostate cancer differentiation

Albumin-to-alkaline phosphatase ratio as a promising indicator of prognosis in human cancers: is it possible?

ROR1 and ROR2 expression in pancreatic cancer